Exact Mass: 301.2517846

Exact Mass Matches: 301.2517846

Found 127 metabolites which its exact mass value is equals to given mass value 301.2517846, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Sphinganine

D-Erythro-1,3-dihydroxy-2-aminooctadecane

C18H39NO2 (301.2980634)


Sphinganine, also known as c18-dihydrosphingosine or safingol, is a member of the class of compounds known as 1,2-aminoalcohols. 1,2-aminoalcohols are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom. Thus, sphinganine is considered to be a sphingoid base lipid molecule. Sphinganine is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Sphinganine can be found in a number of food items such as agar, biscuit, herbs and spices, and pasta, which makes sphinganine a potential biomarker for the consumption of these food products. Sphinganine can be found primarily in blood, feces, and urine, as well as throughout most human tissues. Sphinganine exists in all eukaryotes, ranging from yeast to humans. In humans, sphinganine is involved in few metabolic pathways, which include globoid cell leukodystrophy, metachromatic leukodystrophy (MLD), and sphingolipid metabolism. Sphinganine is also involved in few metabolic disorders, which include fabry disease, gaucher disease, and krabbe disease. Moreover, sphinganine is found to be associated with pregnancy. Sphinganine is a lyso-sphingolipid protein kinase inhibitor. It has the molecular formula C18H39NO2 and is a colorless solid. Medicinally, safingol has demonstrated promising anticancer potential as a modulator of multi-drug resistance and as an inducer of necrosis. The administration of safingol alone has not been shown to exert a significant effect on tumor cell growth. However, preclinical and clinical studies have shown that combining safingol with conventional chemotherapy agents such as fenretinide, vinblastine, irinotecan and mitomycin C can dramatically potentiate their antitumor effects. Currently in Phase I clinical trials, it is believed to be safe to co-administer with cisplatin . Sphinganine belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom. Thus, sphinganine is considered to be a sphingoid base lipid molecule. Sphinganine is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Sphinganine exists in all living species, ranging from bacteria to humans. Within humans, sphinganine participates in a number of enzymatic reactions. In particular, sphinganine can be converted into 3-dehydrosphinganine through its interaction with the enzyme 3-ketodihydrosphingosine reductase. In addition, sphinganine can be converted into sphinganine 1-phosphate; which is catalyzed by the enzyme sphingosine kinase 2. Outside of the human body, sphinganine has been detected, but not quantified in, several different foods, such as Mexican oregano, jostaberries, winter squash, angelica, and epazotes. This could make sphinganine a potential biomarker for the consumption of these foods. Sphinganine blocks postlysosomal cholesterol transport by inhibiting low-density lipoprotein-induced esterification of cholesterol and causing unesterified cholesterol to accumulate in perinuclear vesicles. It has been suggested that endogenous sphinganine may inhibit cholesterol transport in Niemann-Pick Type C (NPC) disease (PMID: 1817037). D004791 - Enzyme Inhibitors KEIO_ID D078 D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity. D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity.

   

Trihexyphenidyl

Pharmaceutical associates brand OF trihexyphenidyl hydrochloride

C20H31NO (301.2405516)


Trihexyphenidyl is only found in individuals that have used or taken this drug. It is one of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic. [PubChem]Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinsons disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement. D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

(2E,6E,8E)-N-Isobutyl-2,6,8-hexadecatriene-10-yneamide

(E,E,E)-N-(2-Methylpropyl)hexadeca-2,6,8-trien-10-ynamide

C20H31NO (301.2405516)


   

2,6 Dimethylheptanoyl carnitine

3-[(2,6-Dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H31NO4 (301.2252966)


2,6 dimethylheptanoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] 2,6 dimethylheptanoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

Nonanoylcarnitine

3-(Nonanoyloxy)-4-(trimethylammonio)butanoic acid

C16H31NO4 (301.2252966)


Nonanoylcarnitine is an acylcarnitine. More specifically, it is an nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Nonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 28695330, PMID: 33391503), pregnancy (PMID: 24704061 - in serum of pregnant women with fetus with CHD). It is also decreased in the urine of individuals with obesity (PMID: 26910390). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

6-Methyloctanoylcarnitine

3-[(6-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2252966)


6-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methyloctanoylcarnitine

3-[(5-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2252966)


5-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methyloctanoylcarnitine

3-[(4-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2252966)


4-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methyloctanoylcarnitine

3-[(7-Methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H31NO4 (301.2252966)


7-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methyloctanoylcarnitine

3-[(3-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2252966)


3-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Threonine

2-Dodecanoylamino-3-hydroxybutanoic acid

C16H31NO4 (301.2252966)


N-lauroyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

C19H27NO2 (301.20416819999997)


   

(2R,3R)-2-Aminooctadecane-1,3-diol

(2R,3R)-2-Aminooctadecane-1,3-diol

C18H39NO2 (301.2980634)


   

Deramciclane

dimethyl[2-({1,7,7-trimethyl-2-phenylbicyclo[2.2.1]heptan-2-yl}oxy)ethyl]amine

C20H31NO (301.2405516)


   

ent-kaur-16-en-19-oate

5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C20H29O2 (301.2167434)


Ent-kaur-16-en-19-oate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Ent-kaur-16-en-19-oate can be found in a number of food items such as tronchuda cabbage, garden rhubarb, quince, and spelt, which makes ent-kaur-16-en-19-oate a potential biomarker for the consumption of these food products.

   
   
   

hexadeca-2E, 7Z-dienoic acid pyrrolide

hexadeca-2E, 7Z-dienoic acid pyrrolide

C20H31NO (301.2405516)


   

(E,E)-2,4-decadienoic acid p-methoxyphenethylamide

(E,E)-2,4-decadienoic acid p-methoxyphenethylamide

C19H27NO2 (301.20416819999997)


   

hexadeca-2E,7Z-dien-10-ynoic acid pyrrolidide

hexadeca-2E,7Z-dien-10-ynoic acid pyrrolidide

C20H31NO (301.2405516)


   
   
   

(1(14)-E,3S,4R,7S,8S,11R,12S,13R)-7-methylaminoisoneoamphilecta-1(14),15-diene.v|7-methylaminoisoneoamphilecta-1(14),15-diene

(1(14)-E,3S,4R,7S,8S,11R,12S,13R)-7-methylaminoisoneoamphilecta-1(14),15-diene.v|7-methylaminoisoneoamphilecta-1(14),15-diene

C21H35N (301.27693500000004)


   
   

9-Hydroxy-1-Methyl-2-nonyl-4(1H)-quinolinone

9-Hydroxy-1-Methyl-2-nonyl-4(1H)-quinolinone

C19H27NO2 (301.20416819999997)


   

hexadeca-6E,8E-dien-10-ynoic acid pyrrolidide

hexadeca-6E,8E-dien-10-ynoic acid pyrrolidide

C20H31NO (301.2405516)


   
   

2,9-Pentadecadiene-12,14-diynoic acid(2-hydroxyisobutyl)amide|pentadeca-2t,9c-dien-12,14-diynoic acid (2-hydroxyisobutyl)amide

2,9-Pentadecadiene-12,14-diynoic acid(2-hydroxyisobutyl)amide|pentadeca-2t,9c-dien-12,14-diynoic acid (2-hydroxyisobutyl)amide

C19H27NO2 (301.20416819999997)


   
   
   

DErySphinganine

DErySphinganine

C18H39NO2 (301.2980634)


Acquisition and generation of the data is financially supported by the Max-Planck-Society

   

MLS001066334-01!D-erythro-Dihydrosphingosine764-22-7

MLS001066334-01!D-erythro-Dihydrosphingosine764-22-7

C18H39NO2 (301.2980634)


   

Sphinganine

D-erythro-2-Amino-1,3-octadecanediol

C18H39NO2 (301.2980634)


A 2-aminooctadecane-1,3-diol having (2S,3R)-configuration. D004791 - Enzyme Inhibitors D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity. D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity. DL-erythro-Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2)[1][2].

   

Dihydrosphingosine

L-erythro Sphinganine (d18:0)

C18H39NO2 (301.2980634)


D004791 - Enzyme Inhibitors D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity. D-Erythro-dihydrosphingosin directly inhibits cytosolic phospholipase A2α (cPLA2α) activity. DL-erythro-Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2)[1][2].

   

Tetradecyldiethanolamine

2-[2-hydroxyethyl(tetradecyl)amino]ethanol

C18H39NO2 (301.2980634)


CONFIDENCE standard compound; INTERNAL_ID 1002; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9366; ORIGINAL_PRECURSOR_SCAN_NO 9363 CONFIDENCE standard compound; INTERNAL_ID 1002; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9364; ORIGINAL_PRECURSOR_SCAN_NO 9362 CONFIDENCE standard compound; INTERNAL_ID 1002; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9357; ORIGINAL_PRECURSOR_SCAN_NO 9355 CONFIDENCE standard compound; INTERNAL_ID 1002; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9378; ORIGINAL_PRECURSOR_SCAN_NO 9377 CONFIDENCE standard compound; INTERNAL_ID 1002; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9396; ORIGINAL_PRECURSOR_SCAN_NO 9394 CONFIDENCE standard compound; INTERNAL_ID 1002; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9391; ORIGINAL_PRECURSOR_SCAN_NO 9389

   

Sphinganine (d18:0)

Sphinganine (d18:0)

C18H39NO2 (301.2980634)


   
   
   

Cyclohexanone, 4-[1-hydroxy-1-phenyl-3-(1-pyrrolidinyl)propyl]-

Cyclohexanone, 4-[1-hydroxy-1-phenyl-3-(1-pyrrolidinyl)propyl]-

C19H27NO2 (301.20416819999997)


   

2S-aminooctadecane-1,3R-diol

Safingol ( L-threo-sphinganine)

C18H39NO2 (301.2980634)


   

Enigmol

2S-aminooctadecane-3S,5S-diol

C18H39NO2 (301.2980634)


   

Dimethyl heptanoyl carnitine

2,6 dimethylheptanoyl carnitine

C16H31NO4 (301.2252966)


   

CAR 9:0

3-[(2,6-dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2252966)


   

NA 16:1;O3

N-(3-Hydroxytetradecanoyl) glycine

C16H31NO4 (301.2252966)


   

2-(carboxymethyl-dodecyl-amino)acetic acid

2-(carboxymethyl-dodecyl-amino)acetic acid

C16H31NO4 (301.2252966)


   

4-(1-Methyl-4-piperidyl)phenylboronic Acid Pinacol Ester

4-(1-Methyl-4-piperidyl)phenylboronic Acid Pinacol Ester

C18H28BNO2 (301.2212978)


   

Tetrabutylammonium Acetate

Tetrabutylammonium Acetate

C18H39NO2 (301.2980634)


   

(1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate

[1R-(1alpha,4abeta,4balpha,10aalpha)]-1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(isopropyl)phenanthrene-1-carboxylic acid, copper salt

C20H29O2- (301.2167434)


   
   

TERT-BUTYL 3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

TERT-BUTYL 3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

C19H27NO2 (301.20416819999997)


   

decanoic acid, compound with dibutylamine (1:1)

decanoic acid, compound with dibutylamine (1:1)

C18H39NO2 (301.2980634)


   

Safingol

DL-erythro-Dihydrosphingosine

C18H39NO2 (301.2980634)


C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor D004791 - Enzyme Inhibitors DL-erythro-Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2)[1][2].

   

2-Cyanoethyltetraisopropylphosphorodiamidite

2-Cyanoethyltetraisopropylphosphorodiamidite

C15H32N3OP (301.2282872)


   

tetra-n-butylammonium dihydrogentrifluoride

tetra-n-butylammonium dihydrogentrifluoride

C16H38F3N (301.2956184)


   

Deramciclane

Deramciclane

C20H31NO (301.2405516)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants Deramciclane has a high affinity for 5-HT2A and 5-HT2C receptors; it acts as an antagonist at both receptor subtypes and has inverse agonist properties at the 5-HT2C receptors without direct stimulatory agonist.

   

1-DODECYLPYRIDINIUM CHLORIDE HYDRATE

1-DODECYLPYRIDINIUM CHLORIDE HYDRATE

C17H32ClNO (301.2172292)


   

4-(2,4-DI-TERT-PENTYLPHENOXY)BUTANENITRILE

4-(2,4-DI-TERT-PENTYLPHENOXY)BUTANENITRILE

C20H31NO (301.2405516)


   

4-(PIPERIDIN-1-YLMETHYL)BENZENEBORONIC ACID, PINACOL ESTER 972-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]-1,2-OXAZINANE

4-(PIPERIDIN-1-YLMETHYL)BENZENEBORONIC ACID, PINACOL ESTER 972-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]-1,2-OXAZINANE

C18H28BNO2 (301.2212978)


   
   

1-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]PIPERIDINE

1-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]PIPERIDINE

C18H28BNO2 (301.2212978)


   

Boc-11-aminoundecanoic acid

Boc-11-aminoundecanoic acid

C16H31NO4 (301.2252966)


   

N-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)CYCLOPENTANAMINE

N-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)CYCLOPENTANAMINE

C18H28BNO2 (301.2212978)


   

N-(6-methoxyquinolin-8-yl)-N-propan-2-yl-pentane-1,4-diamine

N-(6-methoxyquinolin-8-yl)-N-propan-2-yl-pentane-1,4-diamine

C18H27N3O (301.2154012)


   

acetic acid,N,N-dimethyltetradecan-1-amine

acetic acid,N,N-dimethyltetradecan-1-amine

C18H39NO2 (301.2980634)


   

DL-THREO-DIHYDROSPHINGOSINE

DL-1,3-DIHYDROXY-2-AMINO-OCTADECANE

C18H39NO2 (301.2980634)


D004791 - Enzyme Inhibitors DL-erythro-Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2)[1][2].

   

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

C19H27NO2 (301.20416819999997)


   

ent-kaur-16-en-19-oate

5,9-Dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate

C20H29O2- (301.2167434)


Ent-kaur-16-en-19-oate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Ent-kaur-16-en-19-oate can be found in a number of food items such as tronchuda cabbage, garden rhubarb, quince, and spelt, which makes ent-kaur-16-en-19-oate a potential biomarker for the consumption of these food products.

   

ent-Kaur-16-en-19-Oate

ent-Kaur-16-en-19-Oate

C20H29O2- (301.2167434)


A monocarboxylic acid anion that is the conjugate base of ent-kaur-16-en-19-oic acid, obtained by deprotonation of the carboxy group.

   

(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoate

(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoate

C20H29O2- (301.2167434)


   

9beta-Pimara-7,15-dien-19-oate

9beta-Pimara-7,15-dien-19-oate

C20H29O2- (301.2167434)


   

(5Z,7E,9E,14Z,17Z)-icosapentaenoate

(5Z,7E,9E,14Z,17Z)-icosapentaenoate

C20H29O2- (301.2167434)


The conjugate base of (5Z,7E,9E,14Z,17Z)-icosapentaenoic acid; major species at pH 7.3.

   
   

(1R,4aR,4bS,7S)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2H-phenanthrene-1-carboxylate

(1R,4aR,4bS,7S)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2H-phenanthrene-1-carboxylate

C20H29O2- (301.2167434)


   

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-ylidene-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylate

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-ylidene-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylate

C20H29O2- (301.2167434)


   

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,9,10,10a-octahydrophenanthrene-1-carboxylate

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,9,10,10a-octahydrophenanthrene-1-carboxylate

C20H29O2- (301.2167434)


   

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,5,6,9,10,10a-octahydrophenanthrene-1-carboxylate

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,5,6,9,10,10a-octahydrophenanthrene-1-carboxylate

C20H29O2- (301.2167434)


   

6-Methyloctanoylcarnitine

6-Methyloctanoylcarnitine

C16H31NO4 (301.2252966)


   

5-Methyloctanoylcarnitine

5-Methyloctanoylcarnitine

C16H31NO4 (301.2252966)


   

4-Methyloctanoylcarnitine

4-Methyloctanoylcarnitine

C16H31NO4 (301.2252966)


   

3-Methyloctanoylcarnitine

3-Methyloctanoylcarnitine

C16H31NO4 (301.2252966)


   
   

(R)-2,6-dimethylheptanoylcarnitine

(R)-2,6-dimethylheptanoylcarnitine

C16H31NO4 (301.2252966)


An optically active form of 2,6-dimethylheptanoylcarnitine having (R)-configuration.

   

O-nonanoyl-L-carnitine

O-nonanoyl-L-carnitine

C16H31NO4 (301.2252966)


The L-enantiomer of O-nonanoylcarnitine.

   

N-tetradecanoyl-(2S)-hydroxyglycine

N-tetradecanoyl-(2S)-hydroxyglycine

C16H31NO4 (301.2252966)


   

All-trans-13,14-dihydroretinoate

All-trans-13,14-dihydroretinoate

C20H29O2- (301.2167434)


   

N-(1,3-dihydroxypentadecan-2-yl)acetamide

N-(1,3-dihydroxypentadecan-2-yl)acetamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxynonan-2-yl)octanamide

N-(1,3-dihydroxynonan-2-yl)octanamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxyoctan-2-yl)nonanamide

N-(1,3-dihydroxyoctan-2-yl)nonanamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxydecan-2-yl)heptanamide

N-(1,3-dihydroxydecan-2-yl)heptanamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxytetradecan-2-yl)propanamide

N-(1,3-dihydroxytetradecan-2-yl)propanamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxytridecan-2-yl)butanamide

N-(1,3-dihydroxytridecan-2-yl)butanamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxyundecan-2-yl)hexanamide

N-(1,3-dihydroxyundecan-2-yl)hexanamide

C17H35NO3 (301.26168)


   

N-(1,3-dihydroxydodecan-2-yl)pentanamide

N-(1,3-dihydroxydodecan-2-yl)pentanamide

C17H35NO3 (301.26168)


   

trihexyphenidyl

Trihexylphenedyl

C20H31NO (301.2405516)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

(E,E,E)-N-(2-Methylpropyl)hexadeca-2,6,8-trien-10-ynamide

(E,E,E)-N-(2-Methylpropyl)hexadeca-2,6,8-trien-10-ynamide

C20H31NO (301.2405516)


   
   
   

3-[(2,6-dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

3-[(2,6-dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2252966)


   

7-Methyloctanoylcarnitine

7-Methyloctanoylcarnitine

C16H31NO4 (301.2252966)


   

O-nonanoylcarnitine

O-nonanoylcarnitine

C16H31NO4 (301.2252966)


A C9-acylcarnitine having nonanoyl as the acyl substituent.

   

all-cis-5,8,11,14,17-icosapentaenoate

all-cis-5,8,11,14,17-icosapentaenoate

C20H29O2 (301.2167434)


An icosapentaenoate that is the conjugate base of all-cis-5,8,11,14,17-icosapentaenoic acid, arising from deprotonation of the carboxylic acid group.

   

2,6-Dimethylheptanoyl carnitine

2,6-Dimethylheptanoyl carnitine

C16H31NO4 (301.2252966)


A C9-acylcarnitine in which the acyl group specified is 2,6-dimethylheptanoyl.

   

Sphingosine (d18:0)

SPH(d18:0)

C18H39NO2 (301.2980634)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   

(6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

(6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.20416819999997)


   

1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H31NO (301.2405516)


   

1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

C20H31NO (301.2405516)


   

(2s,4e,6e)-12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

(2s,4e,6e)-12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

C19H27NO2 (301.20416819999997)


   

(2e,6e,8e)-n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

(2e,6e,8e)-n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

C20H31NO (301.2405516)


   

(2r,6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

(2r,6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.20416819999997)


   

12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

C19H27NO2 (301.20416819999997)


   

(2e,9z)-n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

(2e,9z)-n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

C19H27NO2 (301.20416819999997)


   

(2e,7z)-1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

(2e,7z)-1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

C20H31NO (301.2405516)


   

[(4as,6ar,10as,11ar,11br)-4,6a,10,11b-tetramethyl-1h,2h,5h,6h,8h,10ah,11h,11ah-naphtho[1,2-b]pyrrolizin-4a-yl]methanol

[(4as,6ar,10as,11ar,11br)-4,6a,10,11b-tetramethyl-1h,2h,5h,6h,8h,10ah,11h,11ah-naphtho[1,2-b]pyrrolizin-4a-yl]methanol

C20H31NO (301.2405516)


   

(2e,7z)-1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

(2e,7z)-1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H31NO (301.2405516)


   

n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

C20H31NO (301.2405516)


   

(2e,4e)-n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

C19H27NO2 (301.20416819999997)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbutanamide

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbutanamide

C19H27NO2 (301.20416819999997)


   

12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.20416819999997)


   

1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

C20H31NO (301.2405516)


   

(6e,8e)-1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

(6e,8e)-1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

C20H31NO (301.2405516)


   

n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

C19H27NO2 (301.20416819999997)


   

n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

C19H27NO2 (301.20416819999997)